Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$8.93
▼ $0.25 (-2.7%)
Market data updated: 09/21 10:40 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$83.60M
Day Range
$8.78 - $9.24
52-Week Range
$6.01 - $17.44
Beta
—
Next Earnings
03.11.2026
Support
$7.42
Resistance
$9.97
ACET is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-29.8% (1Y)
Strengths: 9/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 20.5%
Growth
Biggest negative driver
Death Cross
SMA 50 recently crossed below SMA 200
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
55
Value
50
Momentum
41
Risk
46
Sentiment
68
Fundamental
34
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Adicet Bio, Inc. has focused on its strong investor interest and clinical progress. Analysts project a **258% potential stock upside**, citing positive earnings revisions, while the company outperforms peers in medical stocks this year. Key updates include the **completion of a Phase 1 study for prula-cel (ADI-001) in lupus patients**, CEO Chen Schor’s upcoming **fireside chat at the H.C. Wainwright Global Investment Conference**, and a recent **Nasdaq inducement grant**. The narrative emphasizes its pipeline in autoimmune diseases, malignancies, and solid tumors.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Adicet Bio, Inc.. News trend score: 68. Reason: 6 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
16
🎯 Conviction (vs. Emotion)
52
Psychology
17
Fundamentals
34
Technical
41
Valuation
50
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+10%
Market Narrative
47
Fundamental Reality
52
Narrative Gap
-5
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ACET’s dominant **anchoring** suggests traders are fixating on the 1.8% gap below resistance, likely using it as a reference point for entry/exit decisions. The **FOMO** score (31) and **euphoria** (22) indicate mild excitement, but neither is extreme—momentum is modest, and sentiment remains balanced. The **overconfidence** score (8) hints at a disconnect between price gains (+3.4% ROC) and slower earnings growth (+0.2% EPS), possibly signaling selective optimism. The key question: *Will traders break the resistance anchor, or will the 1.8% gap hold as a psychological barrier?*
Updated: 09/08/2026, 10:43 PM
What could change this?
👥 What the crowd believes
"average of price targets set by Wall Street analysts indicates a potential upside of 258.2%"
"FDA has cleared the Company’s Investigational New Drug (IND) application for ADI-212"
"completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prula-cel"
"Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Philip Fisher — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for ACET reflects deep methodological differences in how these investors weigh risk, valuation, and market psychology. Benjamin Graham’s models—both defensive and enterprising—see a clear statistical discount, rating it as a standout opportunity, while Walter Bagehot’s liquidity focus still finds it resilient in a crisis. In contrast, Fisher and Nelson’s frameworks dismiss it outright, either for lacking fundamental depth or showing overbought cycle traits, while Malkiel/Bogle and Schwager’s disciplined approaches treat it as a non-starter, favoring passive or trendless strategies. Meanwhile, Marks and Loeb’s caution stems from concerns over inflated expectations or outright risk, while Lynch and Smith’s growth/dividend frameworks lack sufficient data to form a conviction. The contrast underscores whether ACET’s fundamentals justify its valuation (Graham) or if it’s already priced for perfection (Marks/Housel), or simply too murky for rigorous analysis (Fisher/Smith).
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 99
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 77
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 63
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 58
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 58
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 53
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 46
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 46
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 40
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 33
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 32
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 6 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-290.3%
Net Margin
-279.3%
EBITDA Margin
—
ROE
-62.7%
ROA
-53.1%
ROIC
—
EPS
-$16.95
Cash
$38.92M
Total Debt
—
Current Ratio
7.47
Debt/Equity
0.01
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$8.93
Estimated Fair Value (DCF)
-$262.54
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-106.68M | $-97.87M |
| 2 | 8.1% | $-115.35M | $-97.09M |
| 3 | 6.3% | $-122.56M | $-94.64M |
| 4 | 4.4% | $-127.92M | $-90.62M |
| 5 | 2.5% | $-131.12M | $-85.22M |
Base FCF (last actual year)
$-96.98M
Terminal Value
$-2.07B
Present Value of Terminal Value
$-1.34B
Enterprise Value
$-1.81B
Net Debt
$0
Equity Value
$-1.81B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$16.61
Tangible Book Value per Share (Tangible NAV)
$7.63
Sentiment based on basic keywords (not AI) — 6 positive, 11 neutral, 3 negative out of the last 20 articles.
Benzinga · 18.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 2.9.2026
Business Wire · 2.9.2026
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Yahoo · 31.8.2026
Business Wire · 31.8.2026
MT Newswires · 27.8.2026
Yahoo · 27.8.2026
Business Wire · 27.8.2026
Benzinga · 27.8.2026
Yahoo · 24.8.2026
Zacks · 24.8.2026
Zacks · 18.8.2026
Zacks · 14.8.2026
SeekingAlpha · 14.8.2026
Adicet Bio, Inc. (ACET) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ACET currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ACET's technical score is 41/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 20.5%; Debt/equity: 0.01; Current ratio: 7.47.
Based on the real signals StockIQ computed: SMA 50 recently crossed below SMA 200; Operating margin: -290.3% (negative); Net margin: -279.3% (negative).
StockIQ has no recorded dividend payment history for ACET.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 3 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Klickstein Lloyd | Grant/Award from Employer | 5.8.2026 | 18,300 | +18,300 | — |
| Klickstein Lloyd | Grant/Award from Employer | 5.8.2026 | 18,300 | +18,300 | — |
| Grissinger Michael | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Klickstein Lloyd | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Chodakewitz Jeffrey | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Sinclair Andrew | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Peng Katie | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| DUBIN STEVE | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| DUBIN STEVE | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Chodakewitz Jeffrey | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Grissinger Michael | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Sinclair Andrew | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Klickstein Lloyd | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Peng Katie | Grant/Award from Employer | 21.6.2026 | 4,200 | +4,200 | — |
| Aftab Blake | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| Schor Chen | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| Schor Chen | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| Aftab Blake | Grant/Award from Employer | 19.6.2026 | 55,000 | +55,000 | — |
| RA CAPITAL MANAGEMENT, L.P. | Other Transaction | 27.4.2026 | 250,000 | -250,000 | — |
| RA CAPITAL MANAGEMENT, L.P. | Other Transaction | 27.4.2026 | 250,000 | +250,000 | — |
| RA Capital Healthcare Fund LP | Other Transaction | 27.4.2026 | 932,624 | -250,000 | — |
| RA Capital Healthcare Fund LP | Other Transaction | 27.4.2026 | 1,402,833 | +250,000 | — |
| ORBIMED ADVISORS LLC | Open Market Sale | 8.4.2026 | 40,416 | -40,416 | $6.52 |
| ORBIMED ADVISORS LLC | Open Market Sale | 8.4.2026 | 32,523 | -32,523 | $6.29 |
| ORBIMED ADVISORS LLC | Open Market Sale | 8.4.2026 | 0 | -40,416 | $6.52 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
252,663 shares short as of 2026-08-31 · vs. 397,053 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
49.4% of trading volume this week was short selling, vs. 41.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology